Mechanism of Action
NPR-B / cGMP Signaling
CNP binds NPR-B (also called GC-B), a transmembrane guanylyl cyclase that generates cGMP intracellularly upon ligand binding. cGMP activates PKG (protein kinase G), which phosphorylates multiple targets including VASP (vasodilator-stimulated phosphoprotein), myosin light chain phosphatase, and PDE5 (phosphodiesterase 5). In vascular smooth muscle, cGMP-mediated relaxation produces vasodilation. CNP also activates NPR-C (clearance receptor), which internalizes and degrades CNP, limiting its local signaling duration.
Bone Growth and Chondrocyte Function
CNP is the most potent local regulator of endochondral bone growth, acting on NPR-B in chondrocytes of the growth plate. It promotes chondrocyte proliferation, differentiation, and extracellular matrix production via cGMP/PKG signaling that activates MAPK ERK2 and upregulates collagen II and aggrecan. NPR-B loss-of-function mutations cause severe short stature in mice and humans (similar to achondroplasia). Conversely, NPR-B activation by CNP/vosoritide stimulates growth plate elongation, the therapeutic basis for achondroplasia treatment.
Cardiovascular and Neural Effects
In the cardiovascular system, CNP acts as an endothelium-derived vasodilator via EDHF mechanisms (K+ channel activation through cGMP) and reduces vascular smooth muscle proliferation. In the brain, CNP is produced by astrocytes and neurons and may modulate synaptic plasticity and neuroinflammation. CNP in the heart improves diastolic function by reducing cardiomyocyte stiffness via cGMP/PKG-mediated titin phosphorylation, the same mechanism explored for heart failure with preserved ejection fraction (HFpEF).
Research Summary
Achondroplasia (FDA Approved)
Clinical / ApprovedVosoritide (modified CNP analogue with extended half-life) received FDA approval in 2021 for achondroplasia in children 5+ years. The pivotal trial showed 1.57 cm/year greater height velocity versus placebo. Mechanism involves FGFR3 (the mutated gene in achondroplasia) normally suppressing CNP/NPR-B signaling; vosoritide bypasses this suppression to restore growth plate chondrocyte function. Phase III data showed improved body proportions and quality-of-life measures.
Heart Failure with Preserved EF
Phase IICNP promotes cGMP-mediated titin N2B phosphorylation in cardiomyocytes, reducing myocardial stiffness. This is a key mechanism for improving diastolic compliance in HFpEF. CNP infusion reduces LV filling pressures acutely. Phase II studies of CNP analogues/prodrugs for HFpEF are ongoing. Combined with PDE5 inhibitors (sildenafil) to prevent cGMP degradation, CNP effects are amplified.
Vascular Biology
PreclinicalCNP inhibits vascular smooth muscle proliferation and neointimal formation after balloon injury, suggesting potential for preventing restenosis after angioplasty. It reduces endothelial inflammation by suppressing NFkB and ICAM-1 via cGMP. Local CNP delivery in stents and vascular grafts is being explored for anti-restenotic applications.
Calculate your CNP dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Cardiovascular vasodilation | 100-800 ng/kg/min IV infusion | Acute 30-60 min infusion | IV |
| Bone growth (preclinical) | 100-400 nmol/kg SC | Once or twice daily x 2-8 weeks | SC |
| Achondroplasia (vosoritide) | 15 mcg/kg SC | Once daily | SC (approved dose) |
Native CNP has a very short half-life (2-3 minutes IV). Vosoritide and other CNP analogues are engineered for prolonged duration. NPR-C clearance receptor reduces endogenous CNP rapidly.
Interactions
Safety Profile
Vosoritide clinical trials in achondroplasia report mild to moderate injection site reactions, transient hypotension (due to vasodilatory effects), and asymptomatic decreases in blood pressure. No serious adverse events related to the mechanism were reported in pediatric trials. IV CNP infusion studies in healthy volunteers show dose-dependent hypotension requiring dose titration. The lack of natriuretic effects (CNP is non-diuretic at physiological doses) distinguishes CNP from ANP/BNP and limits fluid balance disturbances.
References
- [1]Yasoda A, et al. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med. 2004.
- [2]Savarirayan R, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3 trial. Lancet. 2020.
- [3]Del Ry S, et al. C-type natriuretic peptide (CNP) in cardiovascular physiology and disease. Peptides. 2013.